Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 2/20 | 0.60 |
| ▸ | TFPI | P10646 | 1/20 | 0.57 |
| ▸ | VIPR1 | P32241 | 3/20 | 0.56 |
| ▸ | VIPR2 | P41587 | 4/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | ECE1 | P42892 | 1/20 | 0.54 |
| ▸ | GLP1R | P43220 | 1/20 | 0.54 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.54 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.54 |
| ▸ | NPY1R | P25929 | 2/20 | 0.53 |
| ▸ | NPY2R | P49146 | 2/20 | 0.53 |
| ▸ | NPY4R | P50391 | 2/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30512795 | 0.95 | KISS1R (0.62) | KISS1RTFPIVIPR1VIPR2OPRM1 | |
| SCHEMBL29746772 | 0.94 | KISS1R (0.60) | KISS1RTFPIVIPR1VIPR2OPRM1 | |
| SCHEMBL29746858 | 0.93 | PTH1R (0.60) | TFPIVIPR1VIPR2GLP1RPTH1R | |
| SCHEMBL29475317 | 0.93 | OPRM1 (0.58) | KISS1RTFPIOPRM1OPRD1OPRK1 | |
| SCHEMBL29475318 | 0.93 | OPRM1 (0.58) | KISS1RTFPIOPRM1OPRD1OPRK1 | |
| SCHEMBL6437697 | 0.92 | TFPI (0.63) | KISS1RTFPIVIPR1VIPR2ECE1 | |
| SCHEMBL6437703 | 0.92 | TFPI (0.63) | KISS1RTFPIVIPR1VIPR2ECE1 | |
| SCHEMBL30553847 | 0.92 | TFPI (0.58) | KISS1RTFPIOPRM1OPRD1OPRK1 | |
| SCHEMBL30367254 | 0.91 | TFPI (0.59) | TFPIVIPR1VIPR2GLP1RPTH1R | |
| SCHEMBL29353526 | 0.91 | TFPI (0.59) | TFPIVIPR1VIPR2GLP1RPTH1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351561-B2 | Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-07-08 | — | — | US | disclosed |
| US-20240327360-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2024-10-03 | — | — | US | disclosed |
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | disclosed |
| US-11919888-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-03-05 | — | — | US | disclosed |
| US-11851443-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-11718591-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| US-11642332-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-11634413-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-11547687-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220298173-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-22 | — | — | US | disclosed |
| US-20220242836-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-08-04 | — | — | US | disclosed |
| EP-3256446-B1 | (2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID AS NEPRILYSIN INHIBITOR | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3099668-B1 | 5-BIPHENYL-4-HETEROARYLCARBONYLAMINO-PENTANOIC ACID DERIVATIVES AS NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-07 | — | — | US | disclosed |
| US-11261197-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | KISS1R 1562/4885TFPI 189/4885VIPR1 184/4885 |
| US-11718591-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof | MME, CTSC, REN | KISS1R 4296/4885TFPI 402/4885VIPR1 814/4885 |
| US-11547687-B2 | Neprilysin inhibitors | MME, REN, ACE | KISS1R 1562/4885TFPI 189/4885VIPR1 184/4885 |
| US-12351561-B2 | Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof | MME, CTSC, REN | KISS1R 4287/4885TFPI 378/4885VIPR1 736/4885 |
| US-20220242836-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | MME, CTSC, REN | KISS1R 4287/4885TFPI 378/4885VIPR1 736/4885 |
| US-20240327360-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | MME, CTSC, REN | KISS1R 4287/4885TFPI 378/4885VIPR1 736/4885 |
| US-11261197-B2 | Neprilysin inhibitors | MME, REN, ACE | KISS1R 1496/4885TFPI 187/4885VIPR1 144/4885 |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | KISS1R 2153/4885TFPI 184/4885VIPR1 128/4885 |
| US-11634413-B2 | Neprilysin inhibitors | MME, REN, ACE | KISS1R 2153/4885TFPI 184/4885VIPR1 128/4885 |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | KISS1R 2153/4885TFPI 184/4885VIPR1 128/4885 |
| US-20220298173-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | KISS1R 1396/4885TFPI 197/4885VIPR1 160/4885 |
| US-11851443-B2 | Neprilysin inhibitors | MME, REN, ACE | KISS1R 1496/4885TFPI 187/4885VIPR1 144/4885 |
| US-12016835-B2 | Neprilysin inhibitors | MME, REN, ACE | KISS1R 1562/4885TFPI 189/4885VIPR1 184/4885 |
| US-11642332-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | MME, DNPEP, TMPRSS15 | KISS1R 4380/4885TFPI 651/4885VIPR1 1569/4885 |
| US-11919888-B2 | Neprilysin inhibitors | MME, REN, ACE | KISS1R 2153/4885TFPI 184/4885VIPR1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.